LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

LLY

750.56

-0.47%↓

JNJ

154.95

-0.91%↓

UNH

378.95

-2.72%↓

ABBV

187.37

+0.69%↑

ABT

134.34

-0.6%↓

Search

Phreesia Inc

Aperta

SettoreSettore sanitario

25.56 3.27

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.48

Massimo

25.92

Metriche Chiave

By Trading Economics

Entrata

8M

-6.4M

Vendite

2.9M

110M

EPS

0.185

Margine di Profitto

-5.826

Dipendenti

2,082

EBITDA

8.4M

2.1M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+28.4% upside

Dividendi

By Dow Jones

Utili prossimi

28 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

108M

1.5B

Apertura precedente

22.29

Chiusura precedente

25.56

Notizie sul Sentiment di mercato

By Acuity

50%

50%

195 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Phreesia Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 mag 2025, 23:59 UTC

Notizie principali
Utili

Naver 1Q Net Slumps on Higher Costs

8 mag 2025, 23:39 UTC

Utili

OCBC 1Q Net Down on Lower Interest Income

8 mag 2025, 23:01 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mag 2025, 22:52 UTC

Utili

REA Expects Annual Listings Growth Despite April Decline

8 mag 2025, 22:46 UTC

Utili

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mag 2025, 23:41 UTC

Discorsi di Mercato

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mag 2025, 23:30 UTC

Utili

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mag 2025, 23:29 UTC

Utili

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mag 2025, 23:22 UTC

Utili

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mag 2025, 23:21 UTC

Utili

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mag 2025, 23:17 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mag 2025, 23:05 UTC

Discorsi di Mercato

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mag 2025, 23:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 mag 2025, 23:01 UTC

Notizie principali

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mag 2025, 22:28 UTC

Utili

REA Expects FY 2025 Listings Growth of 1-2%

8 mag 2025, 22:28 UTC

Utili

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mag 2025, 22:27 UTC

Utili

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mag 2025, 22:27 UTC

Utili

REA Says April Residential Listings Fell by 11% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mag 2025, 22:26 UTC

Utili

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mag 2025, 22:26 UTC

Utili

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mag 2025, 22:25 UTC

Utili

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Confronto tra pari

Modifica del prezzo

Phreesia Inc Previsione

Obiettivo di Prezzo

By TipRanks

28.4% in crescita

Previsioni per 12 mesi

Media 31.33 USD  28.4%

Alto 35 USD

Basso 28 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Phreesia Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

11

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

25.23 / 25.61Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

195 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Phreesia Inc

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.